Search over 3,000 reports

    Chemotherapy Induced Neutropenia (CIN) -Market Insights, Epidemiology and Market Forecast-2023

    Chemotherapy Induced Neutropenia (CIN) -Market Insights, Epidemiology and Market Forecast-2023
    Date: Nov, 2017
    Type: Pharmaceutical
    Pages: 132
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIMI0002
    DelveInsight's "Chemotherapy Induced Neutropenia (CIN) - Market Insights, Epidemiology
    and Market Forecast-2023" Report provides an overview of the disease and global market
    trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United
    States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE)
    and rest of the world (RoW). The Report covers the therapeutics market revenue, treatment
    practice and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to
    2023 segmented by seven major markets. In addition, the report provides the historical and
    forecasted of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10 cancer
    indications till 2023.
    The report covers the number of patients for 10 cancer indications (i.e., Breast Cancer,
    Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer,
    Ovarian Cancer, Hodgkin's disease and Non-Hodgkin Lymphoma), who are at risk of developing
    CIN as an adverse event of the chemotherapies of respective cancers.
    Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for
    chemotherapy-induced neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was
    later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute
    to majority of the market size, of CIN. However, New Chemical Entities are expected to launch
    in the near future. According to DelveInsight, the worldwide CIN market is estimated to
    increase at a CAGR of 3.37% for the forecast period i.e., 2013-2023.
    The report is built using data and information sourced from proprietary databases, primary and
    secondary research and in-house Forecast model analysis by Publisher team of industry experts.
    Report Introduction
    Chemotherapy Induced Neutropenia (CIN) Market Overview at a Glance
    Global Market Size of CIN in 2016
    Global Market Size of CIN in 2023
    Chemotherapy Induced Neutropenia (CIN)
    Overview
    Causes of Neutropenia
    Common cycle of chemotherapy-related neutropenia
    Signs and symptoms
    Risk Factors
    Severity and Grades of Neutropenia
    Pathophysiology/ Mechanisms of action
    Diagnosis
    Epidemiology and Patient Population
    Assumptions and Caveats
    United States
    Incident Cases of ten major Cancer indications in United States
    Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
    indications in United States
    Ten major cancer patients at low risk of CIN in United States
    Ten major cancer patients at intermediate to high risk of CIN in United States
    Europe
    Germany
    Incident Cases of ten major Cancer indications in Germany
    Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
    indications in Germany
    Ten major cancer patients at low risk of CIN in Germany
    Ten major cancer patients at intermediate to high risk of CIN in Germany
    United Kingdom
    Incident Cases of ten major Cancer indications in United Kingdom
    Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
    indications in United Kingdom
    Ten major cancer patients at low risk of CIN in United Kingdom
    Ten major cancer patients at intermediate to high risk of CIN in United Kingdom
    Italy
    Incident Cases of ten major Cancer indications in Italy
    Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
    indications in Italy
    Ten major cancer patients at low risk of CIN in Italy
    Ten major cancer patients at intermediate to high risk of CIN in Italy
    Spain
    Incident Cases of ten major Cancer indications in Spain
    Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
    indications in Spain
    Ten major cancer patients at low risk of CIN in Spain
    Ten major cancer patients at intermediate to high risk of CIN in Spain
    France
    Incident Cases of ten major Cancer indications in France
    Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
    indications in France
    Ten major cancer patients at low risk of CIN in France
    Ten major cancer patients at intermediate to high risk of CIN in France
    Japan
    Incident Cases of ten major Cancer indications in Japan
    Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
    indications in Japan
    Ten major cancer patients at low risk of CIN in Japan
    Ten major cancer patients at intermediate to high risk of CIN in Japan
    Treatment Algorithm
    NCCN Guidelines for Chemotherapy Induced Febrile Neutropenia
    Evaluation prior to First Chemotherapy Cycle
    Overall Febrile Neutropenia Risk
    Evaluation Prior to Second and Subsequent Chemotherapy
    Therapeutic use of Granulocyte-colony stimulating factor (G-CSF) for Febrile Neutropenia 73
    European Organisation for Research and Treatment of Cancer (EORTC)
    Marketed Drugs
    List of Marketed Drugs
    Biosimilar Efficacy
    Marketed Drugs Presence
    Neupogen: Amgen
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Safety and Efficacy of Neupogen
    Product Profile
    Neupogen Historical Sales (2013-2015)
    Neulasta: Amgen
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Safety and Efficacy of Neulasta
    Product Profile
    Neulasta Historical Sales (2013-2015)
    Zarxio: Sandoz
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Safety and Efficacy of Zarxio
    Product Profile
    Granix: Teva Pharmaceuticals
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Safety and Efficacy of Granix
    Product Profile
    Lonquex: Teva Pharmaceuticals
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Safety and Efficacy of Lonquex
    Product Profile
    Tevagrastim: Teva Pharmaceuticals
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Product Profile
    Filgrastim BS Injection: Fuji Pharma Co., Ltd.
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Product Profile
    Emerging Therapies
    Biologicals/ Biosimilar Pipeline
    New Chemical Entity (NCE) Pipeline
    Pipeline Drugs Results
    Plinabulin: BeyondSpring Pharmaceuticals, Inc.
    Clinical Development
    Advantages & Disadvantages
    Product Profile
    Rolontis: Spectrum Pharmaceuticals, Inc.
    Clinical Development
    Advantages & Disadvantages
    Product Profile
    CHS-1701: Coherus Biosciences
    Clinical Development
    Advantages & Disadvantages
    Product Profile
    Myelo001: Myelo Therapeutics GmbH
    Clinical Development
    Advantages & Disadvantages
    Product Profile
    Market outlook- Chemotherapy Induced Neutropenia (CIN)
    Market Size
    Assumptions and Caveats
    1. Forecasting Events
    2. Drug Categories, Chemotherapy Cycles & Dosage, and Cost Assumptions
    Global CIN: Country-Wise Market Analysis
    Global Market Size of CIN (2013-2023)
    Market Size of CIN in 7MM (2013-2023)
    United States
    Europe
    Germany
    France
    Italy
    Spain
    United Kingdom
    Rest of Europe (RoE)
    Japan
    Rest of World (RoW)
    Market Drivers
    Market Restraints
    Unmet Needs
    Appendix
    Report Methodology
    Consulting Services
    Disclaimer
    About DelveInsight
    Table 1: Grades of Neutropenia
    Table 2: Incident Cases of ten major Cancer indications in United States (2013-2023)
    Table 3: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in
    United States (2013-2023)
    Table 4: Ten major cancer patients at low risk of CIN in United States (2013-2023)
    Table 5: Ten major cancer patients at intermediate to high risk of CIN in United States (2013-2023)
    Table 6: Incident Cases of ten major Cancer indications in Germany (2013-2023)
    Table 7: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in
    Germany (2013-2023)
    Table 8: Ten major cancer patients at low risk of CIN in Germany (2013-2023) 32
    Table 9: Ten major cancer patients at intermediate to high risk of CIN in Germany (2013-2023)
    Table 10: Incident Cases of ten major Cancer indications in United Kingdom (2013-2023)
    Table 11: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications
    in United Kingdom (2013-2023)
    Table 12: Ten major cancer patients at low risk of CIN in United Kingdom (2013-2023)
    Table 13: Ten major cancer patients at intermediate to high risk of CIN in United Kingdom (2013-2023)
    Table 14: Incident Cases of ten major Cancer indications in Italy (2013-2023)
    Table 15: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications
    in Italy (2013-2023)
    Table 16: Ten major cancer patients at low risk of CIN in Italy (2013-2023)
    Table 17: Ten major cancer patients at intermediate to high risk of CIN in Italy (2013-2023)
    Table 18: Incident Cases of ten major Cancer indications in Spain (2013-2023)
    Table 19: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications
    in Spain (2013-2023)
    Table 20: Ten major cancer patients at low risk of CIN in Spain (2013-2023)
    Table 21: Ten major cancer patients at intermediate to high risk of CIN in Spain (2013-2023)
    Table 22: Incident Cases of ten major Cancer indications in France (2013-2023)
    Table 23: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications
    in France (2013-2023)
    Table 24: Ten major cancer patients at low risk of CIN in France (2013-2023)
    Table 25: Ten major cancer patients at intermediate to high risk of CIN in France (2013-2023)
    Table 26: Incident Cases of ten major Cancer indications in Japan(2013-2023)
    Table 27: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications
    in Japan (2013-2023)
    Table 28: Ten major cancer patients at low risk of CIN in Japan (2013-2023)
    Table 29: Ten major cancer patients at intermediate to high risk of CIN in Japan (2013-2023)
    Table 30: List of Marketed Drugs for Chemotherapy Induced Neutropenia
    Table 31: Biosimilar Efficacy of Drugs for Chemotherapy Induced Neutropenia
    Table 32: Marketed Drugs Presence for Chemotherapy Induced Neutropenia
    Table 33: List of Biosimilar Pipeline Drugs for Chemotherapy Induced Neutropenia
    Table 34: List of Biosimilar Pipeline Drugs for Chemotherapy Induced Neutropenia
    Table 35: Results of Pipeline Drugs for Chemotherapy Induced Neutropenia
    Table 36: Global Market size of CIN in USD Billion (2013-2023)
    Table 37: Market Size of CIN in 7MM (USD, Billion) (2013-2023)
    Table 38: United States Market Size of CIN in USD, Billion (2013-2023)
    Table 39: Germany Market Size of CIN in USD, Billion (2013-2023)
    Table 40: France Market Size of CIN in USD, Billion (2013-2023)
    Table 41: Italy Market Size of CIN in USD, Billion (2013-2023)
    Table 42: Spain Market Size of CIN in USD, Billion (2013-2023)
    Table 43: United Kingdom Market Size of CIN in USD, Billion (2013-2023)
    Table 44: RoE Market Size of CIN in USD, Billion (2013-2023)
    Table 45: Japan Market Size of CIN in USD, Billion (2013-2023)
    Table 46:RoW Market Size of CIN in USD, Billion (2013-2023)
    Figure 1: Incident Cases of ten major Cancer indications in United States (2013-2023)
    Figure 2: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in United States (2013-2023)
    Figure 3: Ten major cancer patients at low risk of CIN in United States (2013-2023)
    Figure 4: Ten major cancer patients at intermediate to high risk of CIN in United States (2013-2023)
    Figure 5: Incident Cases of ten major Cancer indications in Germany (2013-2023)
    Figure 6: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in Germany (2013-2023)
    Figure 7: Ten major cancer patients at low risk of CIN in Germany (2013-2023)
    Figure 8: Ten major cancer patients at intermediate to high risk of CIN in Germany (2013-2023)
    Figure 9: Incident Cases of ten major Cancer indications in United Kingdom (2013-2023)
    Figure 10: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in United Kingdom (2013-2023)
    Figure 11: Ten major cancer patients at low risk of CIN in United Kingdom (2013-2023)
    Figure 12: Ten major cancer patients at intermediate to high risk of CIN in United Kingdom (2013-2023)
    Figure 13: Incident Cases of ten major Cancer indications in Italy (2013-2023)
    Figure 14: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in Italy (2013-2023)
    Figure 15: Ten major cancer patients at low risk of CIN in Italy (2013-2023)
    Figure 16: Ten major cancer patients at intermediate to high risk of CIN in Italy (2013-2023)
    Figure 17: Incident Cases of ten major Cancer indications in Spain (2013-2023)
    Figure 18: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in Spain (2013-2023)
    Figure 19: Ten major cancer patients at low risk of CIN in Spain (2013-2023)
    Figure 20: Ten major cancer patients at intermediate to high risk of CIN in Spain (2013-2023)
    Figure 21: Incident Cases of ten major Cancer indications in France (2013-2023)
    Figure 22: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in France (2013-2023)
    Figure 23: Ten major cancer patients at low risk of CIN in France (2013-2023)
    Figure 24: Ten major cancer patients at intermediate to high risk of CIN in France (2013-2023)
    Figure 25: Incident Cases of ten major Cancer indications in Japan (2013-2023)
    Figure 26: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications inJapan (2013-2023)
    Figure 27: Ten major cancer patients at low risk of CIN in Japan (2013-2023)
    Figure 28: Ten major cancer patients at intermediate to high risk of CIN in Japan (2013-2023)
    Figure 29: Evaluation Prior to Second and Subsequent Chemotherapy
    Figure 30: Therapeutic use of Granulocyte-colony stimulating factor (G-CSF) for Febrile Neutropenia
    Figure 31: EORTC Patient assessment algorithm to decide prophylactic G-CSF Usage
    Figure 32: Historical Sales of Neupogen (2013-2015)
    Figure 33: Historical Sales of Neulasta (2013-2015)
    Figure 34: Percentage of Market share as per Category (2013-2023)
    Figure 35: Global Market Size of CIN in USD, Billion (2013-2023)
    Figure 36: Market Size of CIN in 7MM (USD, Billion) (2013-2023)
    Figure 37: United States Market Size of CIN in USD, Billion (2013-2023)
    Figure 38: Germany Market Size of CIN in USD, Billion (2013-2023)
    Figure 39: France Market Size of CIN in USD, Billion (2013-2023)
    Figure 40: Italy Market Size of CIN in USD, Billion (2013-2023)
    Figure 41: Spain Market Size of CIN in USD, Billion (2013-2023)
    Figure 42: United Kingdom Market Size of CIN in USD, Billion (2013-2023)
    Figure 43: RoE Market Size of CIN in USD, Billion (2013-2023)
    Figure 44: Japan Market Size of CIN in USD, Billion (2013-2023)
    Figure 45: RoW Market Size of CIN in USD, Billion (2013-2023)
    Chemotherapy Induced Neutropenia Market (7MM)

    Chemotherapy Induced Neutropenia Market forecasting

    Chemotherapy Induced Neutropenia Sales forecasting

    Chemotherapy Induced Neutropenia Market segments

    Chemotherapy Induced Neutropenia Epidemiology

    Chemotherapy Induced Neutropenia Pipeline products and technologies

    Chemotherapy Induced Neutropenia Competitive landscape

    Chemotherapy Induced Neutropenia SWOT analysis

    Chemotherapy Induced Neutropenia Market Driver's and barriers

    Chemotherapy Induced Neutropenia Key Companies and Funding

    • Single User License
      (20% Off)
      $4,950.00
      $3960
    • Site License
      (30% Off)
      $9,900.00
      $6930
    • Global License
      (40% Off)
      $14,850.00
      $8910

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap